S&P Futures
4,054.75 -1.00 (-0.02%) Dow Futures
32,581.00 -19.00 (-0.06%) Nasdaq Futures
12,257.25 -22.00 (-0.18%) Russell 2000 Futures
1,837.20 +0.90 (+0.05%) Crude Oil
113.75 -0.34 (-0.30%) Gold
1,861.10 +7.20 (+0.39%)
Athersys, Inc. (ATHX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.1849 |
| Open | 0.1903 |
| Bid | 0.0000 x 36100 |
| Ask | 0.0000 x 4000 |
| Day's Range | 0.1824 - 0.1985 |
| 52 Week Range | 0.1800 - 1.8100 |
| Volume | |
| Avg. Volume | 4,478,757 |
| Market Cap | 49.807M |
| Beta (5Y Monthly) | -1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3570 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.56 |
- Zacks
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
- Benzinga
Athersys-Partnered Japanese Ischemic Stroke Study Disappoints, Shares Plunge
Athersys Inc's (NASDAQ: ATHX) partner, Healios K.K. has reported topline results for its Japan ischemic stroke study, TREASURE. The study included patients with moderate to moderate-severe ischemic stroke administered a single dose of MultiStem cells (invimestrocel) or placebo by intravenous infusion within 18-36 hours of the event. The primary endpoint, Excellent Outcome at 90 days, did not reach statistical significance in this population. Overall, consistent improvement in essentially all mea
- Business Wire
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study
CLEVELAND, Ohio, May 20, 2022--Topline data from the largest cell therapy clinical trial ever run in Japan, evaluating Athersys' MultiStem (invimestrocel) for ischemic stroke.
